Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
135.42
+0.46 (0.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $622.10M in the quarter ending September 30, 2024, with 24.72% growth. This brings the company's revenue in the last twelve months to $2.24B, up 25.72% year-over-year. In the year 2023, Neurocrine Biosciences had annual revenue of $1.89B with 26.76% growth.
Revenue (ttm)
$2.24B
Revenue Growth
+25.72%
P/S Ratio
6.04
Revenue / Employee
$1,602,000
Employees
1,400
Market Cap
13.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG | 21.46B |
Baxter International | 15.06B |
Viatris | 15.05B |
Avantor | 6.82B |
Moderna | 5.08B |
Incyte | 4.08B |
Dr. Reddy's Laboratories | 3.58B |
Revvity | 2.72B |
NBIX News
- 1 day ago - Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 3 days ago - Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
- 8 days ago - Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 8 days ago - US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters
- 25 days ago - Neurocrine Biosciences to Participate at Investor Conferences in December - PRNewsWire
- 6 weeks ago - Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels - Seeking Alpha
- 6 weeks ago - Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Participate at Investor Conferences in November - PRNewsWire